Immunotherapy combination for children with recurrent brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests two immunotherapy drugs (fianlimab and cemiplimab) together in children and young adults with recurrent or progressive high-grade glioma or ependymoma—aggressive brain tumors that have come back or gotten worse. The goal is to see if combining these immune-boosting treatments can help fight these tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have come back or progressed (gotten worse) and be confirmed by MRI scan and biopsy
- You must be healthy enough to consider surgery to remove the tumor
- You must have a good overall health status (functional ability score of 50 or higher)
- Your organs (liver, kidneys, blood counts) must be working adequately
- You cannot have had prior immunotherapy drugs targeting PD-1, PD-L1, LAG3, or CTLA-4
- You cannot have an active autoimmune disease requiring treatment in the past 2 years, or history of heart inflammation (myocarditis) or lung inflammation (interstitial lung disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs, actimab-A and cemiplimab, for people whose glioblastoma has come back after prior treatment. The goal is to see if this combination can improve outcomes.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) for people with newly diagnosed, advanced head and neck cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help shrink or control the cancer.
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
Hear when a new High-Grade Glioma (HGG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.